JP2020528409A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528409A5 JP2020528409A5 JP2020502405A JP2020502405A JP2020528409A5 JP 2020528409 A5 JP2020528409 A5 JP 2020528409A5 JP 2020502405 A JP2020502405 A JP 2020502405A JP 2020502405 A JP2020502405 A JP 2020502405A JP 2020528409 A5 JP2020528409 A5 JP 2020528409A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- unit dosage
- single unit
- subject
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023093929A JP2023123523A (ja) | 2017-07-20 | 2023-06-07 | Ｈｉｖの処置における使用のための、ダルナビル、コビシスタット、エムトリシタビン、及びテノホビルアラフェナミドを含む組成物 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762534885P | 2017-07-20 | 2017-07-20 | |
| US62/534,885 | 2017-07-20 | ||
| US201762571384P | 2017-10-12 | 2017-10-12 | |
| US62/571,384 | 2017-10-12 | ||
| US201862623174P | 2018-01-29 | 2018-01-29 | |
| US62/623,174 | 2018-01-29 | ||
| US201862665339P | 2018-05-01 | 2018-05-01 | |
| US62/665,339 | 2018-05-01 | ||
| PCT/US2018/042937 WO2019018676A1 (en) | 2017-07-20 | 2018-07-19 | COMPOSITIONS COMPRISING DARUNAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FOR USE IN THE TREATMENT OF HIV |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023093929A Division JP2023123523A (ja) | 2017-07-20 | 2023-06-07 | Ｈｉｖの処置における使用のための、ダルナビル、コビシスタット、エムトリシタビン、及びテノホビルアラフェナミドを含む組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020528409A JP2020528409A (ja) | 2020-09-24 |
| JP2020528409A5 true JP2020528409A5 (enExample) | 2021-08-26 |
Family
ID=63168494
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020502405A Withdrawn JP2020528409A (ja) | 2017-07-20 | 2018-07-19 | Ｈｉｖの処置における使用のための、ダルナビル、コビシスタット、エムトリシタビン、及びテノホビルアラフェナミドを含む組成物 |
| JP2023093929A Pending JP2023123523A (ja) | 2017-07-20 | 2023-06-07 | Ｈｉｖの処置における使用のための、ダルナビル、コビシスタット、エムトリシタビン、及びテノホビルアラフェナミドを含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023093929A Pending JP2023123523A (ja) | 2017-07-20 | 2023-06-07 | Ｈｉｖの処置における使用のための、ダルナビル、コビシスタット、エムトリシタビン、及びテノホビルアラフェナミドを含む組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10786518B2 (enExample) |
| EP (3) | EP4696309A3 (enExample) |
| JP (2) | JP2020528409A (enExample) |
| AU (1) | AU2018304373B2 (enExample) |
| BR (1) | BR112020000842A2 (enExample) |
| CA (1) | CA3070713A1 (enExample) |
| CL (1) | CL2020000136A1 (enExample) |
| MA (1) | MA49635A (enExample) |
| MX (1) | MX2020000694A (enExample) |
| WO (1) | WO2019018676A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021180963A1 (en) * | 2020-03-13 | 2021-09-16 | Janssen Sciences Ireland Unlimited Company | A protease inhibitor regimen for treating subjects infected with hiv |
| CN111419811A (zh) * | 2020-05-20 | 2020-07-17 | 北京华睿鼎信科技有限公司 | 一种富马酸替诺福韦艾拉酚胺组合物 |
| CN119700779B (zh) * | 2024-11-28 | 2025-11-04 | 安徽贝克生物制药有限公司 | 一种达芦那韦和考比司他复合片剂及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2920110A (en) | 1952-12-11 | 1960-01-05 | Ethyl Corp | Preparation of meta dichloro- and dibromo-benzenes |
| TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| CN103841962B (zh) | 2011-07-07 | 2016-08-17 | 爱尔兰詹森科学公司 | 地瑞纳韦配制品 |
| PL2729130T3 (pl) * | 2011-07-07 | 2018-02-28 | Janssen Sciences Ireland Uc | Preparaty kombinowane darunawiru |
| AU2012327170A1 (en) * | 2012-02-03 | 2013-08-22 | Gilead Sciences, Inc. | Therapeutic compounds |
| AU2015373104B2 (en) * | 2015-01-03 | 2020-07-09 | Mylan Laboratories Limited | Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof |
-
2018
- 2018-07-19 MX MX2020000694A patent/MX2020000694A/es unknown
- 2018-07-19 AU AU2018304373A patent/AU2018304373B2/en active Active
- 2018-07-19 WO PCT/US2018/042937 patent/WO2019018676A1/en not_active Ceased
- 2018-07-19 EP EP25225254.9A patent/EP4696309A3/en active Pending
- 2018-07-19 MA MA049635A patent/MA49635A/fr unknown
- 2018-07-19 EP EP26182959.2A patent/EP4778527A2/en active Pending
- 2018-07-19 CA CA3070713A patent/CA3070713A1/en active Pending
- 2018-07-19 JP JP2020502405A patent/JP2020528409A/ja not_active Withdrawn
- 2018-07-19 EP EP18753288.2A patent/EP3654951B1/en active Active
- 2018-07-19 BR BR112020000842-7A patent/BR112020000842A2/pt not_active Application Discontinuation
- 2018-07-19 US US16/040,324 patent/US10786518B2/en active Active
-
2020
- 2020-01-16 CL CL2020000136A patent/CL2020000136A1/es unknown
-
2023
- 2023-06-07 JP JP2023093929A patent/JP2023123523A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015318061B2 (en) | Solid forms of a toll-like receptor modulator | |
| JP2018527366A (ja) | ＨＩＶを処置するためのｔｏｌｌ様レセプターのモジュレーター | |
| JP2022009683A (ja) | テノホビルアラフェナミドの結晶形態 | |
| US20160067255A1 (en) | Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir | |
| RU2015110699A (ru) | Фармацевтическая антиретровирусная композиция | |
| AU2016330895A1 (en) | Compounds and combinations for the treatment of HIV | |
| US20190151307A1 (en) | Methods of treating patients co-infected with a virus and tuberculosis | |
| CN112996517A (zh) | 预防hiv的整合酶抑制剂 | |
| JP2020527570A (ja) | 組み合わせ薬物療法 | |
| WO2018005909A1 (en) | Combinations and uses and treatments thereof | |
| WO2017205585A1 (en) | Combinations and uses treatments thereof | |
| WO2018051250A1 (en) | Combination comprising tenofovir alafenamide, bictegravir and 3tc | |
| JP2022538338A5 (enExample) | ||
| JP2022538449A5 (enExample) | ||
| WO2019030626A1 (en) | COMBINATIONS, USES AND CORRESPONDING TREATMENTS | |
| CA3113011C (en) | Integrase inhibitors for the prevention of hiv | |
| WO2018042332A1 (en) | Combinations and uses and treatments thereof | |
| WO2018044853A1 (en) | Combinations and uses and treatments thereof | |
| RU2022102380A (ru) | Способы лечения инфекции, вызванной вич, у пациентов детского возраста с применением рилпивирина | |
| Sidhu et al. | Pharmacokinetic modeling predicts different IgG exposures using different IVIG-SCIG dose conversion factors in patients with primary immune deficiency | |
| HK40048893A (en) | Integrase inhibitors for the prevention of hiv | |
| US20200246351A1 (en) | Combinations and uses and treatments thereof | |
| WO2018044822A1 (en) | Combinations and uses and treatments thereof | |
| WO2018042331A1 (en) | Combinations and uses and treatments thereof | |
| EP3506902A1 (en) | Combinations and uses and treatments thereof |